Biographies: Scientific Advisory Board on Vaping Products

On this page


Steven J. Hoffman, J.D., Ph.D., LL.D.

Steven J. Hoffman is the Director of the Global Strategy Lab, a Professor of Global Health, Law, and Political Science at York University, and the Scientific Director of the Canadian Institutes of Health Research's Institute of Population & Public Health. He holds courtesy appointments as a Professor of Clinical Epidemiology & Biostatistics (Part-Time) at McMaster University and Adjunct Professor of Global Health & Population at Harvard University. He is an international lawyer licensed in both Ontario and New York who specializes in global health law, global governance and institutional design. His research integrates analytical, empirical and big data approaches to craft global regulatory strategies that better address transnational health threats, social inequalities and human rights challenges. Past studies have focused on access to medicines, antimicrobial resistance, health misinformation, pandemics and tobacco control. Currently he is co-principal investigator of a large $4.6 million CAD research consortium on "Strengthening International Collaboration for Capitalizing on Cost-Effective and Life-Saving Commodities (i4C)". He holds a Bachelor of Health Sciences from McMaster University, an MA in Political Science and a Juris Doctor from the University of Toronto, a PhD in Health Policy from Harvard University, and a doctorate in law from Sciences Po Paris.

Board members

Carolyn Baglole, Ph.D., MSc

Dr. Carolyn Baglole received her BSc and MSc from the University of Prince Edward Island, and her PhD from the University of Calgary. She then did postdoctoral research in the fields of lung biology/toxicology and subsequently joined the academic staff in the Department of Environment Medicine at the University of Rochester before returning to Canada. She is currently an Associate Professor in the Departments of Pathology, Pharmacology & Therapeutics and Experimental Medicine at McGill University. She is also the Director of the Histopathology Technology Platform at the Research Institute of the McGill University Health Centre and the Co-Director of the Experimental Pathology Unit.

Dr. Baglole's translational research program is designed to identify novel cellular and molecular pathways that control the pathogenesis of chronic lung diseases associated with exposure to cigarette smoke, air pollution or cannabis. Her main research focus is to understand how these environmental exposures contribute to pathogenic mechanisms such as chronic inflammation and cell death (apoptosis) that drive the development of diseases such as chronic obstructive pulmonary disease (COPD), a prevalent and deadly lung disease almost always caused by cigarette smoke (>90% of cases), as well as lung cancer. There is no cure for individuals afflicted with diseases like COPD, and there are no effective therapies that can reduce disease progression. This is due, in part, to a lack of novel intracellular targets for the development of new pharmacological therapies. Therefore, exploring whether these newly-indentified biological pathways can be used to develop new drugs or be biomarkers to identify individuals at risk for disease is also a major focus of her laboratory.

Linda Bauld B.A., Ph.D., FRCPE

Linda Bauld is the Bruce and John Usher Chair in Public Health in the College of Medicine and Veterinary Medicine at the University of Edinburgh. She is also Deputy Director of the UK Centre for Tobacco and Alcohol Studies, which covers 13 Universities, and holds the CRUK/BUPA Chair in Behavioural Research for Cancer Prevention at Cancer Research UK. She has conducted studies on smoking cessation and tobacco control for the past 20 years and more recently has been active in alcohol and obesity policy research. Linda is a former scientific adviser on tobacco control to the UK government and in 2017 she was elected a Fellow of the Royal College of Physicians of Edinburgh for her contribution to cancer prevention and public health.

Geoffrey T. Fong, Ph.D., FRSC, FCAHS

Dr. Geoffrey Fong is Professor of Psychology and Public Health at the University of Waterloo and Senior Investigator at the Ontario Institute for Cancer Research. Dr. Fong is the Founder and Chief Principal Investigator of the International Tobacco Control Policy Evaluation Project, a research consortium of over 150 researchers across 29 countries covering over two-thirds of the world's tobacco users. Since 2002, the ITC Project has conducted large national longitudinal cohort surveys in those 29 countries to evaluate tobacco control policies of the WHO Framework Convention on Tobacco Control (FCTC). Dr. Fong is the Co-Principal Investigator of a current $15M Program Project Grant from the US National Cancer Institute to the ITC Project to examine in four countries-Canada, US, England, Australia-the factors relating to e-cigarette use, transitions between cigarette smoking, e-cigarette use, dual use, and use of neither product, and the impact of policies and regulations on both tobacco products and e-cigarettes and other nicotine delivery products on direction and magnitude of those transitions. Dr. Fong has contributed to several major scientific reports, including as one of the three Scientific Editors for the 2017 WHO and US National Cancer Institute Monograph, The Economics of Tobacco and Tobacco Control.

Among Dr. Fong's awards are the 2011 CIHR Award for Knowledge Translation, a 2013 WHO World No Tobacco Day Award, a 2015 Luther L. Terry Award from the American Cancer Society for Outstanding Research Contribution, and the 2017 Policy Impact Award from the American Association for Public Opinion Research. He is also a Fellow of the Royal Society of Canada and the Canadian Academy of Health Sciences.

Maciej Goniewicz, Ph.D., PharmD

Maciej Goniewicz is an associate professor of Oncology at the Department of Health Behavior, Roswell Park Cancer Institute in Buffalo, NY. Dr. Goniewicz's primary research area is in nicotine pharmacology, with a focus on nicotine dependence and smoking cessation. He has research experience in smoking cessation behavioral treatment, pharmacotherapy, and pharmacokinetics in both clinical and community-based settings. His current research is focused on new nicotine-containing products and alternative forms of tobacco. These studies include the laboratory evaluation of the products, pharmacological and toxicological assessment, surveys among their users, and their potential application in harm reduction and smoking cessation. Dr. Goniewicz received his Pharm.D. and Ph.D. in Toxicology and Pharmacology from the Medical University of Silesia, Poland.

Lorraine Greaves, Ph.D., DU

Lorraine Greaves PhD is a medical sociologist and Senior Investigator at the Centre of Excellence for Women's Health in Vancouver, Canada and its founding Executive Director from 1997-2009. Dr. Greaves has worked in academic, government, education and NGO settings. She was the Senior Policy Advisor for BC Women's Hospital and Health Centre and Executive Director of the Health Systems Strategy Division of the Ontario Ministry of Health and Long-Term Care. Dr. Greaves is a Clinical Professor in the Faculty of Medicine at UBC and an expert in tobacco, substance use, violence and trauma, and the integration of sex, gender and equity into research, care, program and policy development. She has published over 100 journal articles, hundreds of reports, and ten books, including Smoke Screen: women's smoking and social control, Highs and Lows: Canadian Perspectives on Women and Substance Use (with Poole), Making it Better: gender transformative health promotion (with Poole and Pederson), Transforming Addiction: gender, trauma and transdisciplinarity (with Poole and Boyle) and Designing and Conducting Gender, Sex and Health Research, (with Oliffe). Her latest book is Gender Unchained: notes from the equity frontier (with Poole). Her current research program includes projects such as: integrating sex and gender into the substance use response system in Canada, developing cannabis prevention messaging, introducing trauma-informed practice into YWCA Toronto, and measuring the effects of sex and gender on KT initiatives in response to opioids, cannabis, new nicotine delivery products and binge alcohol use. The funders include Health Canada, Canadian Institutes of Health Research, and the Public Health Agency of Canada, among others. She has received numerous awards, among them the Outstanding Ontario Achievement Award, the Vancouver YWCA Woman of Distinction, the Lifetime Achievement Award from the International Network of Women Against Tobacco (INWAT) and an Honorary Doctorate from the University of Ottawa.

David Hammond, Ph.D., M.Sc.

David Hammond is a Professor, CIHR-PHAC Chair in Applied Public Health. Professor Hammond's research focuses on chronic disease prevention and global health in the areas of tobacco control policy, health diets and obesity prevention, as well as harm reduction and drug policy. He works closely with governments and non-governmental organizations around the world and has served as an Advisor for the World Health Organization. He also serves as an Expert Witness in court cases, primarily on behalf of governments defending health regulations from legal challenges by the food and tobacco industries. Professor Hammond's research has been recognized by awards from the Canadian Institutes of Health Research (CIHR), the Canadian Cancer Society, the Canadian Medical Association, the Royal Statistical Society of Canada, and the World Health Organization. His education includes BA Psychology (1996, University of British Columbia), MSc Health Studies (2002, University of Waterloo) and PhD Psychology (2005, University of Waterloo).

Professor Hammond has previously served as an Advisor to the World Health Organization for Framework Convention on Tobacco Control, which has been ratified by more than 170 countries. Professor Hammond has advised regulatory agencies and governments around the world on tobacco control policy, including the US Centers for Disease Control, Health Canada, the UK Department of Health, the European Commission, and the Commonwealth of Australia. He has also served as an Expert Witness on behalf of the Canadian, UK and Australian governments in litigation against the tobacco industry. Professor Hammond recently received the Canada's Premier Young Researcher Award from the Canadian Institutes of Health Research and is a past recipient of the Canadian Medical Association Journal's Top Canadian Achievements in Health Research Awards 2009 for his work with Geoff Fong and Mary Thompson as part of the International Tobacco Control Policy Evaluation Project, conducted in 29 countries.

Dr. Andrew Pipe CM, BA, MD, LLD (Hons), DSc (Hons)

Dr. Andrew Pipe graduated from Queen's University in 1974. Formerly Chief of the Division of Prevention and Rehabilitation at the University of Ottawa Heart Institute, Dr. Pipe is a Professor in the Faculty of Medicine at the University of Ottawa. Dr. Pipe continues his clinical and research activities within the Division.

He is currently involved in clinical research assessing new approaches to smoking cessation, strategies designed to facilitate exercise adoption, and novel initiatives to prevent cardiovascular disease.

Dr. Pipe has addressed audiences in over 30 nations and is frequently consulted on issues related to tobacco use and smoking cessation, drug use in sport, and physical activity and health. In addition to his clinical responsibilities, Dr. Pipe has been extensively involved in sports and sport medicine for many years. Dr. Pipe served as a physician at 12 Olympic Games and has been the Team Physician for Canada's National Men's Basketball Team since 1978. A member of the Canadian Olympic Hall of Fame, he served as Chair of the Canadian Centre for Ethics in Sport from its inception until 2003. Dr. Pipe is currently Chair of the Board of the Heart and Stroke Foundation of Canada.

Dr. Pipe is the recipient of the International Olympic Committee's Award for "Sport, Health and Wellbeing" and honourary degrees from Queen's University (LLD), Brock University (DSc) and University of Guelph (DSc). He was formerly Vice Chairman of the Board of Trustees at Queen's University. In 2002 he was named to the Order of Canada. Dr. Pipe was recently named as an Honorary Fellow of the Royal College of Physicians and Surgeons of Canada for his dedicated work addressing smoking cessation, tobacco control, drug-free sport and physical activity.

Rachel Tyndale, Ph.D.

Rachel Tyndale PhD is head of Pharmacogenetics at the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, the Canada Research Chair in Pharmacogenomics, and a Professor in the Departments of Pharmacology & Toxicology, and Psychiatry at the University of Toronto. Dr. Tyndale focuses on sources of variation between individuals in drug response in the clinical area of addictions, with a focus on smoking and opioids. Dr. Tyndale seeks to identify and understand risk factors, and underlying mechanisms, in substance abuse and to implement approaches to personalize treatment. Her laboratory program also has a major interest in understanding how interindividual variation in drug metabolizing enzymes within the brain alters drug and toxin effects.

Dr. Tyndale is the recipient of over 40 awards in both clinical and basic pharmacology including the Alton Ochsner Award Relating Smoking and Health and the Society for Research in Nicotine and Tobacco Langley Award. Dr. Tyndale sits on numerous scientific advisory boards, editorial boards, was chair for NIH's PharmacoGenomics Research Network (, and is a lead writer for the 2018 Surgeon General's Report on Tobacco Cessation. Dr. Tyndale has supervised over 100 scientists, post-doctoral fellows and graduate students, published over 300 papers and book chapters, given over 200 invited presentations.

Kenneth E. Warner, Ph.D., M.Phil., A.B.

Kenneth E. Warner is the Avedis Donabedian Distinguished University Professor Emeritus and Dean Emeritus of Public Health at the University of Michigan, where he was a member of the faculty from 1972-2017. An economist, Dr. Warner earned his A.B. degree summa cum laude from Dartmouth College and M.Phil. and Ph.D. degrees from Yale University.

Dr. Warner's research has focused on economic and policy aspects of tobacco control. He served as the Senior Scientific Editor of the 25th anniversary US Surgeon General's report on smoking and health. He also served as the World Bank's representative to negotiations on the Framework Convention on Tobacco Control, the world's first global health treaty. During 2004-05 he was President of the Society for Research on Nicotine and Tobacco. Dr. Warner was a founding member of the Board of Directors of the Truth Initiative and founding Director of the University of Michigan Tobacco Research Network.

Dr. Warner is a recipient of the Surgeon General's Medallion, a Luther L. Terry Award for Exemplary Leadership in Tobacco Control, the Alton Ochsner Award Relating Smoking and Health, and the Doll/Wynder Award from SRNT. He is a member of the US National Academy of Medicine.

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: